SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Patriot Scientific Corp – ‘8-K’ for 4/12/19

On:  Monday, 4/15/19, at 10:15am ET   ·   For:  4/12/19   ·   Accession #:  1683168-19-1027   ·   File #:  0-22182

Previous ‘8-K’:  ‘8-K’ on 4/5/19 for 4/1/19   ·   Next:  ‘8-K’ on 10/4/19 for 10/1/19   ·   Latest:  ‘8-K’ on 3/28/24 for 3/22/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/15/19  Patriot Scientific Corp           8-K:1,9     4/12/19    2:112K                                   GlobalOne Filings Inc/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     14K 
 2: EX-10.1     Consulting Agreement                                HTML     56K 


8-K   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 12, 2019

 

 

 

Patriot Scientific Corporation

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   0-22182   84-1070278

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

   

 

2038 Corte Del Nogal, Suite 141

Carlsbad, CA 92011-1478

 

(Address of Principal Executive Offices, and Zip Code)

 

(760) 795-8517

 

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 C: 
  C:   
 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 12, 2019, Patriot Scientific Corporation (the “Company”) retained Artius Bioconsulting, a California limited liability company (“Artius”), to evaluate the potential of establishing a systems integration company that develops a technology platform based on blockchain technology that could be implemented throughout the drug development process (the “Project”) pursuant to a Consulting Agreement between the Company and Artius effective as of April 12, 2019 (the “Agreement”).

 

Pursuant to the Agreement, Artius will research, analyze and report its findings with respect to the Project in exchange for $151,000, payable in installments upon the completion of certain deliverables to the Company. The deliverables are due at various times over the course of eight weeks. The Company will own the Work Product (as defined in the Agreement). The Agreement has a term of four months, unless terminated earlier pursuant to its terms.

 

The description of the Agreement herein is only a summary and is qualified in its entirety by the full text of such document, which is filed as an exhibit hereto and is incorporated by reference herein.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

See Exhibit Index

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Patriot Scientific Corporation
   
Date: April 15, 2019 By: /s/ Clifford L. Flowers                          
  Clifford L. Flowers
  Chief Financial Officer

 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
10.1 Consulting Agreement effective as of April 12, 2019 between Patriot Scientific Corporation and Artius Bioconsulting.

 

 

 

 C: 

  C: 2 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:4/15/19None on these Dates
For Period End:4/12/19
 List all Filings 
Top
Filing Submission 0001683168-19-001027   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 10:58:08.1am ET